Authors
Latest:
MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell TherapyThe University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.
Latest:
Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCLThe associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
Latest:
Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASHThe lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.
Latest:
Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple MyelomaThe interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.
Latest:
Improve Medicare Policy to Remove Barriers to Bone Marrow and Cord Blood TransplantsReducing barriers to hematopoetic stem cell (HPC) transplant is critical to supporting patients with one of the more than 70 blood cancers and other blood disorders (such as leukemia, lymphoma, and myloplastic dysplasia) for which a transplant may be the only therapy remaining with curative intent.
Latest:
The Conundrum Of Antibacterial Use in Neutropenic Patients Undergoing Chemotherapy for Hematologic Malignancy or HSCTPatients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.
Latest:
Two Gene Therapies Fix Fault in Sickle Cell Disease and ß-thalassemiaTwo gene therapy techniques in separate, concurrently published trials demonstrate clinical success in mitigating monogenic hemoglobinopathies.
Latest:
Stem Cell Therapy Reverses Type 1 DiabetesA novel treatment method called stem cell educator therapy appears to reverse the effects of type 1 diabetes, researchers at the University of Illinois at Chicago and colleagues in China report.
Latest:
Bendamustine Plus Rituximab Bests Current Standard of Care for Indolent LymphomaBendamustine (Treanda) plus rituximab (Rituxan; B/R) was superior to CHOP plus rituximab (CHOP-R) as first-line therapy of indolent lymphoma and mantle cell lymphoma in a multicenter, randomized, controlled trial of the German Study Group on Indolent Lymphoma (StiL). At an oral presentation at the 51st ASH Annual Meeting, experts agreed that this study may be practice-changing.
Latest:
Dr. Margulis on Different Approaches to Adjuvant Therapy in RCCVitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Harshman on Earlier Use of Immunotherapy in RCCLauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Urbanic on the Evolution of Radiation in NSCLCJames Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.
Latest:
Dr. McGregor on Whether Patients Need Frontline Combinations in RCCBradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.
Latest:
Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell LeukemiaJavier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Latest:
Dr. Forster on Next Steps With Lurbinectedin in SCLCMartin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).
Latest:
Dr. Meric-Bernstam on the Activity of Telaglenastat and Cabozantinib in mRCCFunda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell CarcinomaDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Dr. Chao on Minimal Residual Disease in ALLNelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).
Latest:
Dr. Barocas on Adjuvant Sunitinib in Renal Cell CarcinomaDaniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.
Latest:
Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell MalignanciesJohn N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.
Latest:
Dr. Alva on the Shift Toward Combination Therapy in mRCCAjjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Latest:
Dr. Vaishampayan on Systemic Therapy Followed by Cytoreductive Nephrectomy in mRCCUlka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.
Latest:
Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLCJonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.
Latest:
Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLCKaren L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.
Latest:
Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLCTerence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.
Latest:
Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.
